2024
Smartband-based smoking detection and real-time brief mindfulness intervention: findings from a feasibility clinical trial
Horvath M, Pittman B, O’Malley S, Grutman A, Khan N, Gueorguieva R, Brewer J, Garrison K. Smartband-based smoking detection and real-time brief mindfulness intervention: findings from a feasibility clinical trial. Annals Of Medicine 2024, 56: 2352803. PMID: 38823419, PMCID: PMC11146247, DOI: 10.1080/07853890.2024.2352803.Peer-Reviewed Original ResearchConceptsBrief mindfulness interventionsMindfulness exercisesTreatment startersMindfulness interventionSmoking interventionsOnline mindfulness trainingWhite non-HispanicMindfulness trainingTreatment fidelityFeasibility measuresHelpfulness ratingsNon-HispanicDaily smokersPredicting smokingReduce smokingExerciseSmokingCigarette smokingInterventionLow completenessAdherenceParticipantsSmartbandAcceptanceMindfulness
2023
Examining racial differences in smoking outcomes among smokers enrolled in an intravenous nicotine infusion study
Schwartz E, Palmisano A, Gueorguieva R, DeVito E, Sofuoglu M. Examining racial differences in smoking outcomes among smokers enrolled in an intravenous nicotine infusion study. Addictive Behaviors 2023, 140: 107615. PMID: 36640662, PMCID: PMC9911383, DOI: 10.1016/j.addbeh.2023.107615.Peer-Reviewed Original ResearchConceptsSmoking-related illnessesNegative drug effectsNicotine clearanceOvernight abstinenceNicotine infusionDrug effectsMentholated cigarettesWhite individualsBlack individualsAcute pharmacologic effectsSmoking-related morbiditySmoking-related diseasesAdministration of nicotineSmoking-related outcomesSubjective drug effectsShort-term abstinenceLower ratesTrend level differenceLarge racial disparitiesNicotine administrationNicotine dosesTrend-level significancePharmacologic effectsTreatment strategiesOutcome measures
2022
Impact of delivery rate on the acute response to intravenous nicotine: A human laboratory study with implications for regulatory science
De Aquino JP, MacLean RR, Gueorguieva R, DeVito EE, Eid T, Sofuoglu M. Impact of delivery rate on the acute response to intravenous nicotine: A human laboratory study with implications for regulatory science. Addiction Biology 2022, 27: e13161. PMID: 35229960, PMCID: PMC8903077, DOI: 10.1111/adb.13161.Peer-Reviewed Original ResearchConceptsAbuse potentialPositive subjective drug effectsSubjective drug effectsHuman laboratory studiesPositive subjective effectsAttention functionSmoking urgesOvernight abstinencePotential therapeutic effectsEffects of nicotineHeart rate increaseDelivery rateDependent smokersExperimental sessionsSubjective effectsNicotine dependenceIntravenous nicotineBlood pressureSaline infusionAcute effectsTherapeutic effectHeart rateDrug effectsAcute responseCrossover design
2021
The effect of varenicline on smoking and drinking outcomes among Black and White adults with alcohol use disorder and co-occurring cigarette smoking: A secondary analysis of two clinical trials
Haeny AM, Gueorguieva R, Montgomery L, Bold KW, Fucito LM, Wu R, Muvvala SB, Zweben A, O'Malley SS. The effect of varenicline on smoking and drinking outcomes among Black and White adults with alcohol use disorder and co-occurring cigarette smoking: A secondary analysis of two clinical trials. Addictive Behaviors 2021, 122: 106970. PMID: 34216871, PMCID: PMC9426655, DOI: 10.1016/j.addbeh.2021.106970.Peer-Reviewed Original ResearchConceptsEffects of vareniclineAlcohol use disorderCigarette smokingClinical trialsUse disordersWhite adultsEfficacy of vareniclineNumber of drinksVareniclineSmokingPrimary analysisAlcohol treatmentSecondary analysisAlcohol useTrialsBlack participantsDrinking outcomesLinear mixed modelsAdultsWhite peopleWhite participantsMixed modelingCigarettesDisordersTreatment
2020
Data Visualization Tools of Tobacco Product Use Patterns, Transitions and Sex Differences in the PATH Youth Data
Gueorguieva R, Buta E, Simon P, Krishnan-Sarin S, O’Malley S. Data Visualization Tools of Tobacco Product Use Patterns, Transitions and Sex Differences in the PATH Youth Data. Nicotine & Tobacco Research 2020, 22: 1901-1908. PMID: 32219313, PMCID: PMC7542650, DOI: 10.1093/ntr/ntaa056.Peer-Reviewed Original ResearchConceptsTobacco product use patternsMultiple tobacco product useProduct use patternsTobacco product useE-cigarettesProduct useTobacco productsHookah useWave 1Wave 2Common tobacco productsTobacco use patternsE-cigarette useSex differencesInitiation of usePatterns of useHealth StudyAdolescent girlsYear old youthRelative frequencyUnweighted frequenciesCigarettesOlder youthUse patternsPopulation Assessment
2019
Modulation of “Protective” Nicotine Perception and Use Profile by Flavorants: Preliminary Findings in E-cigarettes
DeVito EE, Jensen KP, O’Malley S, Gueorguieva R, Krishnan-Sarin S, Valentine G, Jatlow PI, Sofuoglu M. Modulation of “Protective” Nicotine Perception and Use Profile by Flavorants: Preliminary Findings in E-cigarettes. Nicotine & Tobacco Research 2019, 22: 771-781. PMID: 30995302, PMCID: PMC7368338, DOI: 10.1093/ntr/ntz057.Peer-Reviewed Original ResearchConceptsSubjective drug effectsNicotine-containing e-liquidsSelf-administered more nicotineAversive effectsSingle testing dayE-cigarettesSelf-reported preferencesE-cigarette appealRs16969968 genotypePreliminary findingsUnflavored e-liquidsIndividual differencesDrug effectsAd libitumE-liquidsAversive actionsTobacco productsNicotine effectsLow-risk groupNicotine-free e-liquidsPalatable flavorAversivenessTesting daysNicotinic acetylcholine receptor subunit genesNumber of puffs
2018
Craving to Quit: A Randomized Controlled Trial of Smartphone App–Based Mindfulness Training for Smoking Cessation
Garrison KA, Pal P, O’Malley S, Pittman BP, Gueorguieva R, Rojiani R, Scheinost D, Dallery J, Brewer JA. Craving to Quit: A Randomized Controlled Trial of Smartphone App–Based Mindfulness Training for Smoking Cessation. Nicotine & Tobacco Research 2018, 22: 324-331. PMID: 29917096, PMCID: PMC7297096, DOI: 10.1093/ntr/nty126.Peer-Reviewed Original ResearchConceptsMindfulness trainingExperience samplingPreliminary evidenceSmartphone appPoint prevalence abstinence ratesMindfulnessSmoking cessationTreatment startersSmoking ratesGroup differencesGroup interactionCravingStrong positive associationAbstinence ratesTrainingTreatment completionPositive associationControlled TrialsTreat approachSmokingTrialsCigarettesMonthsAppsAssociationA fMRI study on the impact of advertising for flavored e-cigarettes on susceptible young adults
Garrison KA, O'Malley SS, Gueorguieva R, Krishnan-Sarin S. A fMRI study on the impact of advertising for flavored e-cigarettes on susceptible young adults. Drug And Alcohol Dependence 2018, 186: 233-241. PMID: 29626776, PMCID: PMC5948598, DOI: 10.1016/j.drugalcdep.2018.01.026.Peer-Reviewed Original ResearchConceptsTobacco-flavored e-cigarettesE-cigarettesE-cigarette advertisementsHealth warningsBrain biomarkersWarning labelsYoung adultsSusceptible young adultsE-cigarette health risksE-cigarette conditionsFuture e-cigarette useE-cigarette useFlavored e-cigarettesCigarette conditionCollege-aged young adultsRegular cigarettesNucleus accumbensTobacco productsNucleus accumbens (NAc) activityFMRI studyPositive associationControl imagesHealth risksPoor memoryBiomarkersImpact of E-cigarettes on Smoking and Related Outcomes in Veteran Smokers With Psychiatric Comorbidity
Valentine GW, Hefner K, Jatlow PI, Rosenheck RA, Gueorguieva R, Sofuoglu M. Impact of E-cigarettes on Smoking and Related Outcomes in Veteran Smokers With Psychiatric Comorbidity. Journal Of Dual Diagnosis 2018, 14: 2-13. PMID: 29083287, PMCID: PMC7131866, DOI: 10.1080/15504263.2017.1384877.Peer-Reviewed Original ResearchConceptsE-cigarette usePsychiatric comorbidityCombustible cigarette useE-cigarettesVeteran smokersQuit ratesNicotine dependenceCigarette useVeterans Affairs Health Care SystemAlveolar carbon monoxide levelsOpen-label studySerious adverse eventsSmoking-related deathsFrequent e-cigarette useMain outcome measuresNumber of cigarettesOne-month followEvidence-based treatmentsTobacco-related harmSubstance use disordersGeneral U.S. populationLower quit ratesNicotine delivery systemsCombustible tobacco useHealth care system
2017
Mecamylamine treatment for alcohol dependence: a randomized controlled trial
Petrakis IL, Ralevski E, Gueorguieva R, O'Malley SS, Arias A, Sevarino KA, Jane JS, O'Brien E, Krystal JH. Mecamylamine treatment for alcohol dependence: a randomized controlled trial. Addiction 2017, 113: 6-14. PMID: 28710873, PMCID: PMC5725262, DOI: 10.1111/add.13943.Peer-Reviewed Original ResearchConceptsHeavy drinking daysDrinking daysAlcohol use disorderUse disordersAlcohol consumptionAlcohol dependenceDouble-blind clinical trialNicotinic acetylcholine receptor antagonistWeeks of treatmentAcetylcholine receptor antagonistCurrent alcohol dependenceSignificant differencesTreatment-seeking smokersMecamylamine treatmentPlacebo groupMonth 3Primary outcomeSmoking statusNicotine withdrawalReceptor antagonistNovel pharmacotherapiesClinical trialsManagement therapyMecamylamineTreatment groups
2016
Correlated probit analysis of repeatedly measured ordinal and continuous outcomes with application to the Health and Retirement Study
Grigorova D, Gueorguieva R. Correlated probit analysis of repeatedly measured ordinal and continuous outcomes with application to the Health and Retirement Study. Statistics In Medicine 2016, 35: 4202-4225. PMID: 27222058, DOI: 10.1002/sim.6982.Peer-Reviewed Original Research
2015
Acute alcohol consumption elevates serum bilirubin: An endogenous antioxidant
O’Malley S, Gueorguieva R, Wu R, Jatlow PI. Acute alcohol consumption elevates serum bilirubin: An endogenous antioxidant. Drug And Alcohol Dependence 2015, 149: 87-92. PMID: 25707709, PMCID: PMC4540054, DOI: 10.1016/j.drugalcdep.2015.01.023.Peer-Reviewed Original ResearchConceptsSerum bilirubinAlcohol consumptionBilirubin concentrationReduced riskTotal serum bilirubin concentrationModerate alcohol consumptionFavorable effectSerum bilirubin concentrationIndirect bilirubin concentrationsFuture longitudinal studiesMixed effects regression modelsCause mortalityBlood concentrationsCardiovascular diseaseAlcohol abstinenceHealthy individualsEndogenous antioxidantsBilirubinRandom orderNext morningEffects regression modelsLongitudinal studyNonsmokersAntioxidant propertiesBaseline
2012
Cigarette Smoking Predicts Differential Benefit from Naltrexone for Alcohol Dependence
Fucito LM, Park A, Gulliver SB, Mattson ME, Gueorguieva RV, O'Malley SS. Cigarette Smoking Predicts Differential Benefit from Naltrexone for Alcohol Dependence. Biological Psychiatry 2012, 72: 832-838. PMID: 22541040, PMCID: PMC3410039, DOI: 10.1016/j.biopsych.2012.03.023.Peer-Reviewed Original ResearchConceptsCigarette smokingAlcohol dependenceBehavioral interventionsAlcohol-dependent smokersCombination of medicationsBaseline demographic differencesPoor treatment outcomesPoor treatment responseDrinking outcomesBetter drinking outcomesSevere alcohol dependenceAlcohol-dependent individualsCigarette intakeAlcohol use outcomesMedical managementPharmacological treatmentTreatment outcomesTreatment responseSmokingSmokersCOMBINE StudyAlcoholism typologyDrinking-related variablesTreatment assignmentNonsmokers
2007
Opioid Receptor Gene (OPRM1, OPRK1, and OPRD1) Variants and Response to Naltrexone Treatment for Alcohol Dependence: Results From the VA Cooperative Study
Gelernter J, Gueorguieva R, Kranzler HR, Zhang H, Cramer J, Rosenheck R, Krystal JH, Group T. Opioid Receptor Gene (OPRM1, OPRK1, and OPRD1) Variants and Response to Naltrexone Treatment for Alcohol Dependence: Results From the VA Cooperative Study. Alcohol Clinical And Experimental Research 2007, 31: 555-563. PMID: 17374034, DOI: 10.1111/j.1530-0277.2007.00339.x.Peer-Reviewed Original ResearchMeSH KeywordsAdultAlcoholismConfidence IntervalsDNADouble-Blind MethodExonsFemaleGenetic VariationGenotypeHumansLinear ModelsLogistic ModelsMaleMiddle AgedNaltrexoneNarcotic AntagonistsOdds RatioProportional Hazards ModelsPsychiatric Status Rating ScalesReceptors, Opioid, deltaReceptors, Opioid, kappaReceptors, Opioid, muSmokingTreatment OutcomeUnited StatesUnited States Department of Veterans AffairsConceptsAlcohol dependenceOpioid receptorsTreatment responseVA Cooperative StudyRate of relapsePredictors of responseAlcohol-dependent male subjectsMu-opioid receptorsKappa-opioid receptorsCourse of treatmentShort-term treatmentReceptor gene variantsOpioid receptor geneAsn40Asp polymorphismAvailable medicationsNaltrexone treatmentSpecific pharmacotherapyPretreatment numberDrug naltrexoneNaltrexoneMale subjectsCooperative StudyRelapseHeavy drinkingIndividual single nucleotide polymorphisms
2005
Cortical Gamma-Aminobutyric Acid Levels and the Recovery from Ethanol Dependence: Preliminary Evidence of Modification by Cigarette Smoking
Mason GF, Petrakis IL, de Graaf RA, Gueorguieva R, Guidone E, Coric V, Epperson CN, Rothman DL, Krystal JH. Cortical Gamma-Aminobutyric Acid Levels and the Recovery from Ethanol Dependence: Preliminary Evidence of Modification by Cigarette Smoking. Biological Psychiatry 2005, 59: 85-93. PMID: 16289397, DOI: 10.1016/j.biopsych.2005.06.009.Peer-Reviewed Original ResearchConceptsEthanol-dependent patientsTobacco smokingEthanol dependenceHealthy subjectsN-acetylaspartateCortical gamma-aminobutyric acid (GABA) levelsGamma-aminobutyric acid (GABA) levelsCortical GABA levelsCortical GABA systemAlcohol withdrawal symptomsAcute ethanol withdrawalComorbidity of alcoholismProton magnetic resonance spectroscopyGamma-aminobutyric acidCortical GABASmoking patientsEthanol withdrawalCigarette smokingGABA systemHealthy menWithdrawal symptomsGABA levelsClinical dataNAA levelsWithdrawal severityCortical γ-Aminobutyric Acid Type A–Benzodiazepine Receptors in Recovery From Alcohol Dependence: Relationship to Features of Alcohol Dependence and Cigarette Smoking
Staley JK, Gottschalk C, Petrakis IL, Gueorguieva R, O’Malley S, Baldwin R, Jatlow P, Verhoeff NP, Perry E, Weinzimmer D, Frohlich E, Ruff E, van Dyck CH, Seibyl JP, Innis RB, Krystal JH. Cortical γ-Aminobutyric Acid Type A–Benzodiazepine Receptors in Recovery From Alcohol Dependence: Relationship to Features of Alcohol Dependence and Cigarette Smoking. JAMA Psychiatry 2005, 62: 877-888. PMID: 16061765, DOI: 10.1001/archpsyc.62.8.877.Peer-Reviewed Original ResearchConceptsWeeks of abstinenceIomazenil single-photon emissionSingle photon emissionDays of sobrietyAlcohol dependenceIomazenil uptakeTomographic scanBenzodiazepine receptorsVoxel-based statistical parametric mappingReceptor adaptationDistribution volumeReceptor functionGamma-aminobutyric acid type ABenzodiazepine receptor levelsIodine I 123Reduced receptor functionHuman alcohol dependenceLast alcoholic drinkHealthy comparison groupStatistical parametric mappingAlcohol withdrawalClinical featuresSmoking statusCigarette smokingAcute withdrawalSex, GABA, and nicotine: The impact of smoking on cortical GABA levels across the menstrual cycle as measured with proton magnetic resonance spectroscopy
Epperson CN, O’Malley S, Czarkowski KA, Gueorguieva R, Jatlow P, Sanacora G, Rothman DL, Krystal JH, Mason GF. Sex, GABA, and nicotine: The impact of smoking on cortical GABA levels across the menstrual cycle as measured with proton magnetic resonance spectroscopy. Biological Psychiatry 2005, 57: 44-48. PMID: 15607299, PMCID: PMC4097033, DOI: 10.1016/j.biopsych.2004.09.021.Peer-Reviewed Original ResearchConceptsCortical GABA levelsOccipital cortex GABA concentrationsGABA levelsProton magnetic resonance spectroscopyImpact of nicotineMenstrual cycleGABA concentrationFemale smokersCortical gamma-aminobutyric acid (GABA) levelsUnderwent proton magnetic resonance spectroscopyGamma-aminobutyric acid (GABA) levelsCentral GABAergic functionCortical GABA concentrationsNicotine-dependent menAmino acid neurotransmissionImpact of smokingPotential risk factorsMenstrual cycle phaseShort-term abstinenceGABAergic functionNicotine modulationSmoking menSmoking cessationFollicular phaseSmoking abstinence